Published in Cancer Sci on June 16, 2017
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood (2008) 2.09
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res (2012) 1.84
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract (2013) 1.41
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg (2006) 1.23
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol (2010) 1.23
Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem (2014) 1.17
Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother (2012) 1.16
Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res (2014) 1.02
Hepatocellular carcinoma from an immunologic perspective. Clin Cancer Res (2013) 1.00
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol (2001) 0.93
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology (2012) 0.92
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clin Cancer Res (2015) 0.90
Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother (2005) 0.90
Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res (2001) 0.90
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res (2014) 0.90
Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. Oncol Rep (2011) 0.89
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer (2013) 0.87
Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients. Oncol Rep (2006) 0.78
Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res (2014) 1.02
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients. Cancer Sci (2016) 0.80
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele. Cancer Sci (2015) 0.77
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients. Cancer Immunol Immunother (2015) 0.76
Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine. Cancer Sci (2015) 0.76
Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer. Evid Based Complement Alternat Med (2016) 0.75
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11(+) or -A33(+) allele. Cancer Sci (2017) 0.75
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer Sci (2017) 0.75
Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer. J Immunol Res (2017) 0.75
Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. Cancer Sci (2017) 0.75
Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer. Clin Lung Cancer (2017) 0.75